Among the many ways Trump has shattered White House norms, his impulsive public communications rank among the most consequential. By inspiring investors or spooking them, his...Politicsread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
CNEX, backed by Microsoft and Dell, filed new allegations in a Texas suit accusing China's Huawei and an executive of trade secrets theft.Technologyread more
With Amazon and Walmart facing regulatory hurdles in India, Reliance's Mukesh Ambani isTechnologyread more
Japan's Panasonic said on Thursday it has stopped shipments of certain components to Huawei Technologies to comply with U.S. restrictions on the Chinese company.Technologyread more
Treasury Secretary Steven Mnuchin told CNBC on Wednesday that a trip to Beijing to resume trade negotiations has not been scheduled yet, reducing hopes of a speedy resolution...Asia Marketsread more
Research analyst Adam Jonas, a long-time Tesla bull, said it's extremely unlikely that big tech firms like Apple or Amazon would buy it.Technologyread more
The disclosures come as a federal judge ruled Wednesday that two other banks — Deutsche Bank and Capital One — can give financial documents to Congress, NBC News reports.Politicsread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
The president may have more success in the court fights to come, including appeals in the cases decided this week. But the two losses are nonetheless a dramatic setback for...Politicsread more
"I regard Teva as a very second-rate generic company that's trying to be better run," Cramer said on "Squawk on the Street. "
Cramer said he was trying to develop a thesis as to how Berkshire's Warren Buffett, Amazon's Jeff Bezos and J.P. Morgan's Jamie Dimon could use the generic drugmaker in their endeavor to lower drug prices.
The three announced a venture to cut health-care costs and improve services for their U.S. employees late last month.
"That is a coalition that could rely on generics to bring down pricing," said Cramer, host of CNBC's "Mad Money. " "I don't think the tie-in necessarily fits, but it is amazing that Warren Buffett goes for what I largely regard as the worst of the worst."
The billionaire investor Buffett "does not approach any large buy lightly," Cramer added.
Teva Pharmaceutical declined to comment on Cramer's remarks.
On Wednesday, a quarterly filing showed Berkshire took a $358 million stake in Teva as of the end of the fourth quarter, sending the drugmaker's stock soaring Wednesday and more than 8 percent Thursday.
Teva is working on a comeback amid price erosion and fierce competition.
In a note to clients, Raymond James analyst Elliot Wilbur suggested that the disclosure by the Oracle of Omaha's conglomerate of a stake in the drugmaker was rare for "esteemed investors," but added the billionaire could have done so as part of his mission to lower drug prices.
"Drug costs continue to escalate, Trump is all over prices, and Teva, along with the rest of the generics industry, is part of the solution and not the problem," Wilbur said Wednesday.